32 results about "MMP3" patented technology

Biomarkers, biomarker panels and methods for diagnosing osteoarthritis (OA) are disclosed, using measurement of the expression level of certain polypeptides in a test sample from a subject, including MCP1, IL8, KC, MMP2, MMP3, IL6, MMP1, RANTES, MMP9, IL1B, Apolipoprotein A1, Apolipoprotein E, DCN, CILP and COMP. Related methods for monitoring OA treatment efficacy, diagnostic reagents, and kits are also described.

The invention relates to the technical field of food and medicines, and discloses a composition of a collagen peptide and an elastin peptide, and a preparation method and application of the composition. The composition of the present invention is composed of a collagen peptide and an elastin peptide, wherein the collagen peptide is produced by enzymolysis of a collagen material by pepsin or trypsin, and the elastin peptide is prepared by enzymolysis of an elastin material via papain and/or a complex protease Protamex. According to the present invention, the elastin peptide and collagen peptidein specific molecular weight ranges are prepared by specific processes, and form the composition at a suitable ratio. The composition can significantly increase the content of elastin and collagen indamaged skin at the same time in a small amount of use, significantly increase the content of hyaluronic acid and hydroxyproline and decrease the content of MMP3, and also can inhibit skin inflammatory factors.

Genetic biomarkers for left side colon cancer (LCC) (such as expression levels of an RNA transcript or expression product of NOX4, MMP3, or a combination) and right side colon cancer (RCC) (such as expression levels of an RNA transcript or expression product of CDCX2, FAM69A, or a combination), are disclosed. Methods for using the biomarkers in providing a prognosis of relapse-free survival probability in patients having LCC or RCC are also presented. Prognostic panels using gene expression values of the biomarkers are also presented. Computer implemented methods employing the biomarkers, and as well as for determining relapse-free survival probability in a patient having RCC or LCC are provided. A genetic method for classifying a colon cancer tissue as a RCC or as a LCC is also disclosed.

The present invention concerns methods and compositions for treatment and determination of the presence or likelihood of an individual to have an ocular surface inflammation. In specific embodiments, a sample from the individual is assayed for the expression level of three or more genes, including IL-6, MMP3, MMP9, IFNy, SPRR-IA, HLA-DRA, MUC5AC, K7, and IL17A. Treatment is provided to an individual with ocular surface inflammation based upon the gene analysis.

The invention relates to a separated nucleic acid sequence of a total number born trait related gene MMP3 of a pig in the technical field of genetic engineering. The separated nucleic acid sequence is provided with a sequence shown by an SEQ ID No:1, the length of which is 1346bp; the nucleic acid sequence shows a pair of allele-specific nucleic acid primers the lengths of which are 20bp; the pair of nucleic acid primers is specifically hybridized; and the sequence shown by the SEQ ID No:1 containing an eighth exon, a ninth exon and an eighth intron of the MMP3 gene of the pig is amplified. The implementation and the application of the separated nucleic acid sequence can be used for detecting and judging the quality of total number born traits of the pig; the molecular marker is applied to conduct a marker assisted selection during breeding of the pig, thereby correcting the defect during conventional selection of reproductive traits of the pig; and the separated nucleic acid sequence has important practical significance.

A composition for preventing and/or treating piles contains at least one NO synthetase (NOS) inhibitor, especially iNOS inhibitor, at least one vascular angiogenesis inhibitor, especially VEGF inhibitor, and at least one matrix metal proteinase (MMP) inhibitor, especially MMP1, MMP3, MMP9 and/or MMP12 inhibitor.

Compositions/methods for employing fresh-frozen or FFPE colon cancer tissue in left side colon cancer (LCC) and right-side colon cancer (RCC) disease patients for risk of relapse assessment/stratification is provided (3 strata and a 4 strata methodology). An RCC gene panel of 4 genes (FAM69A, CDX2, FAM84A, ITGA3), and 9 genes (FAM69A, CDX2, ITGA3, FAM84A, ITPRIP, RAB3B, SMAD3, PCSK5, MMP28), is provided. An LCC gene panel of 4 genes (NOX4, WNT5A, MMP3, IBSP), and a 9 genes (MMP3, WINT5A, NOX4, IBSP, SLC16A6, CYPIBI, TFAP2C, MATN3, ANKRD6), is provided. A microchip-based clinical tool, and a kit including a microchip, is presented. The invention also describes a computer-implemented method for assessing relative risk of relapse in LCC and/or RCC disease. An individual patient scoring method that presents a continuous stratification score useful in the post-surgical colon cancer management of LCC and/or RCC patient is also presented.

The invention discloses a functional self-assembly miRNA/polypeptide composite hydrogel suitable for cartilage regeneration and a preparation method of the functional self-assembly miRNA/polypeptide composite hydrogel. The preparation method comprises the following steps: (1) preparing a functional polypeptide aqueous solution; (2) obtaining original miRNA from sample sequencing sources of aged animals and human bodies with arthritis, and further selecting phenotypes of arthritis and aging, including Sox9, Acan, Col2a1, Mmp3, Mmp13, P16INK4a, P21, Adamts4 and Adamts5, by virtue of a fluorescent quantitative PCR (Polymerase Chain Reaction) technology and western blotting, so as to determine the miRNA with the functions of resisting aging and promoting cartilage repair, and further selecting the phenotypes of the arthritis and aging, including Sox9, Acan, Col2a1, Mmp3, Mmp13, P16INK4a, P21, Adamts4 and Adamts5; (3) dissolving the miRNA with the anti-aging and cartilage repair promoting functions determined in the step (2) by using the functional polypeptide aqueous solution to obtain a composite solution; and (4) placing the composite solution in a crosslinking condition for in-situ crosslinking to obtain the functionalized self-assembled miRNA/polypeptide composite hydrogel suitable for cartilage regeneration.

The invention discloses application of a prismatomeria tetrandra monomer in liver protection. The inventor performs high-throughput screening on prismatomeris tetrandra monomeric compounds (HG2, HG3 and HG4) extracted and separated from the ethyl acetate part of prismatomeris tetrandra, the result shows that the number of difference up-regulation genes is 21, and compared with a control group, the Klf15 expression difference has very significant difference. Due to the fact that Klf15 can regulate endogenous and exogenous metabolism of the liver, regulate expression of MMp3 and reduce the liver cell apoptosis level, it can be predicted that a prismatomeria tetrandra monomer can regulate the endogenous and exogenous metabolism of the liver by up-regulating expression of the Klf15 gene, and finally the liver protection effect is achieved. In conclusion, the prismatomeris tetrandra has incalculable potential in research and development of the liver protection medicine, and is worthy of further research and development.

The invention relates to the diagnosis and treatment of diseases, including cancer and inflammatory disorders. The invention provides, and involves the use of, antibodies that bind: i) the IIICS isoform of fibronectin, ii) matrix-metalloproteinase 3 (MMP3), iii) periostin, or iv) tenascin-W.

The invention discloses a composition for combined treatment of solid tumors, and the effective component at least includes an mmp3 antagonistic substance and an oncolytic virus. The composition usesthe mmp3 antagonistic substance and the oncolytic virus to perform combined treatment on the solid tumors, and can effectively inhibit tumor growth and improve survival rate.

The invention belongs to the technical field of biological and medical examination, and relates to a molecular biological method for detecting the expression quantity of tumor-related gene products, and the method can be used for providing references for identification of colorectal cancer change, colorectal cancer classification/type, prognosis evaluation and the like. The related genes comprise: KRT23, KRT80, CA9, FOXQ1, CDH3, KIAA1199, CLDN2, KLK10, CLDN1, GRIN2D, NKD1, C6ORF223, MMP3, MMP11, TRIM29, TESC, GYLTL1B, NKD2, PRSS22, VWA2, REG1A, DPEP1, FABP6, CEL, CELP, CPNE7, RPL13AP20, TNFRSF6B, CYP19A1, RPLP0P2, GUCA2B, AQP8, CA1, GUCA2A, CA2, CLCA4, H19, FAP, NAT1 and the like. The combined application of the genes (single or any combination) is beneficial to providing references for identification, classification/type, prognosis evaluation and the like of the colorectal cancer; when the genes are jointly applied to identify colorectal cancer and normal colorectal tissues, the sensitivity can reach 97% when the specificity is 100%.

The invention relates to a gene molecular marker related to yak physique, a detection method and a kit and belongs to the technical field of molecular biology. By analyzing the genetic polymorphism ofa yak MMP3 gene, one related SNP site, capable of affecting the yak physique, of the MMP3 gene is found. The invention further provides a PCR method for detecting the SNP site. By the method, yak molecular breeding can be well performed.

The invention discloses application of FABP3 to takayasu arteritis vascular fibrosis. According to the invention, by adding radix curcumae longae granules, the progress of the takayasu arteritis vascular fibrosis can be effectively controlled within 6 months, and the levels of pro-fibrotic factors FN1 and MMP9 in serum are reduced to a certain extent; and vascular adventitial fibroblasts (AAF) are transfected by using small interfering RNA and overexpression plasmids, down-regulation or overexpression of the AAF in FABP3 can respectively inhibit or promote expression and cell viability of a proliferation related gene Ki67 in cells, and meanwhile, can inhibit or promote synthesis of FN1, COL11A, COL1, MMP9 and MMP3 from the AAF. According to the invention, FABP3-OE-AAF is intervened in vitro by adopting curcumin, and the curcumin can inhibit the expression of FABP3 and meanwhile, can inhibit the synthesis of cell proliferation and vascular fibrosis related markers. The invention provides a new molecular target for clinical treatment of the takayasu arteritis vascular fibrosis.

The invention relates to application of miltirone in treatment of osteoarthritis. The tanshinone can effectively reduce the expression of chondrolysis promoting genes such as MMP3 and MMP13 secreted by synovial fibroblasts induced by inflammatory factors through a potential action target JUN of the tanshinone, which indicates that the tanshinone has a new application in treating osteoarthritis.

The invention discloses a kit for detecting individual skin genes and a use method of the kit. Allele polymorphisms (SNPs) of four genes, namely MMP1, MMP3, MMP9 and AQP3 are analyzed and identified by adopting a multiple PCR amplification and electrophoresis method. The method comprises the following steps: a) collecting cast-off cells in the oral cavity of a testee and storing the cast-off cells in a collection card or performing DNA nucleic acid extraction on a blood sample; b) adding a saliva collection card sample or an extracted DNA sample of the testee into a reaction system, and carrying out PCR amplification; c) running an amplification program; and d) carrying out electrophoretic analysis on the amplification product, and carrying out interpretation according to a peak pattern graph. According to the invention, the SNP of a plurality of genes related to the testee can be synchronously detected, and simplicity, high efficiency and specificity of detection are realized; and the reference is provided for the skin type of the testee through the analysis.